- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide, Hydrocortisone, Vanicream- Active, Vanicream- Experienced Dupilumab
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 433 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 35
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Adults Growth Hormone Deficiency.
- Interventions
- Pegvisomant, Regular insulin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cancer, Prostate Neoplasms
- Interventions
- goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Prostatic Neoplasms
- Interventions
- GM-CSF, Ketoconazole, Mitoxantrone
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 1,186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 185
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 142 more
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
- Drug
- Lead sponsor
- Peter y. Liu
- Other
- Eligibility
- 22 Years to 45 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Type 1 Diabetes
- Interventions
- Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
- Drug
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Duarte, California • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Interventions
- Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Julio Barredo, MD
- Other
- Eligibility
- 16 Years to 39 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
- Conditions
- Septic Shock
- Interventions
- Hydrocortisone, sodium succinate, Normal saline
- Drug
- Lead sponsor
- Jerry Zimmerman
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 18
- States / cities
- Tucson, Arizona • Los Angeles, California • Oakland, California + 15 more
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS), Subclinical Cushing's, Mild Autonomous Cortisol Excess
- Interventions
- Intervention 1: Adrenalectomy, Intervention 2: Semaglutide
- Procedure · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Shoulder Impingement Syndrome
- Interventions
- Manual Physical Therapy, Corticosteroid Injection
- Procedure
- Lead sponsor
- Madigan Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
- Conditions
- Cushing's Disease
- Interventions
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Torrance, California + 9 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
- Interventions
- Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Infant, Newborn, Diseases, Cardiovascular Insufficiency
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 34 Weeks and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
- Conditions
- Healthy
- Interventions
- Hyperglycemia, Saline, Exercise, Blood Draws, Fasting procedure
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- DUOC-01
- Biological
- Lead sponsor
- Joanne Kurtzberg, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adrenal Hyperplasia, Congenital
- Interventions
- Hydrocortisone sodium acetate
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Month to 21 Years
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 22
- States / cities
- Oakland, California • Orange, California • Aurora, Colorado + 19 more
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 12
- States / cities
- Encino, California • Granada Hills, California • Mission Viejo, California + 9 more